Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-823778 in Atherosclerotic Cardiovascular Disease
NCT01666704Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of bms-823778 in atherosclerotic cardiovascular disease (ASCVD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Fluorodeoxyglucose (FDG) uptake in the index vessel at Day 168. Planned start Apr 2014; status: withdrawn.
02
Drugs
bms-823778
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT01666704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666704.